GlassScriptPhysician profile
Daniel Joseph Ballow
NPI 1811280373
$1,163.83
in general payments reported to CMS, 2019-2025
23 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $55.17 · 2021: $11.12 · 2022: $15.52 · 2023: $190 · 2024: $317 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $209.38 | 2019-2025 | Xtandi, Myrbetriq |
| Allergan, INC. | $93.61 | 2019-2021 | |
| Janssen Biotech, INC. | $87.22 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.53 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $78.84 | 2024 | Orgovyx |
| Antares Pharma, INC. | $75.03 | 2024 | Xyosted |
| Boston Scientific Corporation | $62.64 | 2023-2024 | Ams 700, Watchman |
| Urogen Pharma, INC. | $61.81 | 2023-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $49.20 | 2019 | |
| Abbvie INC. | $45.56 | 2019-2023 | Botox |
| Rochester Medical Corporation | $43.19 | 2019-2020 | |
| Davol INC. | $41.03 | 2019 | |
| Tolmar, INC. | $40.47 | 2023 | |
| Medtronic USA, INC. | $30.33 | 2019 | |
| Axonics, INC. | $29.47 | 2024 | Axonics |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $21.86 | 2024 | Gentlecath Glide |
| Ferring Pharmaceuticals INC. | $18.26 | 2019 | |
| Blue Earth Diagnostics | $16.99 | 2019 | |
| Pfizer INC. | $16.87 | 2019 | |
| Merck Sharp & Dohme LLC | $16.40 | 2023 | Keytruda, Lynparza |
| Urovant Sciences INC | $15.52 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $15.05 | 2019 | |
| Olympus America INC. | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ballow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.